OmniAb 1Q 2026: Revenue $3.99M, Net income ($15.73M), EPS ($0.12) — 10-Q Summary
OmniAb reported 1Q 2026 revenue of $3.99M, up 78.3% YoY, with a net loss of $15.73M and EPS of ($0.12). Nine-month revenue rose 209% to $31.8M, driven by milestone revenue and growth in services and xPloration. Active partners and programs increased to 111 and 433, respectively.
How this was made
The 30-second read
Why it matters
The modest revenue increase does not offset the larger net loss, suggesting short‑term pressure on the share price.
Market read
Micro‑cap biotech earnings release with limited material impact beyond the company's shareholders.
What to watch
Potential pipeline milestones or partnership announcements not disclosed in this filing.
Background
OmniAb is a clinical‑stage biotech focused on antibody and ion‑channel programs. The 10‑Q provides the first detailed quarterly financials for 2026.
Ticker impact
OmniAb released its Q1 2026 10‑Q with revenue of $3.99M, up 78% YoY, and a net loss of $15.73M.
likely downside as investors price in the widening loss
Micro‑cap biotech with a small loss and limited revenue; market typically reacts negatively to widening losses.
Market effects
Biotech sector may see slight drag as a peer reports a widening loss.
U.S. small‑cap biotech investors may adjust positions.
Limited to niche biotech investors.
Counterpoint
If the revenue growth trajectory continues, the stock could be undervalued despite the loss.
Key entities
- companyOmniAb, Inc.
Biotech firm reporting Q1 2026 results.
